Cue Biopharma, Inc. Accumulated Other Comprehensive Income
Cue Biopharma, Inc. (CUE) had Accumulated Other Comprehensive Income of $1.00 thousand as of 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2025-11-12
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $1.00K.
- 2024-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $0.00.
- 2023-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $0.00.
- 2023-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $0.00.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2025-09-30 | $1.00K 10-Q · filed 2025-11-12 | |
| 2024-12-31 | $0.00 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $0.00 10-K · filed 2024-03-28 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-03 | |
| 2023-06-30 | -$5.00K 10-Q · filed 2023-08-08 | |
| 2023-03-31 | -$39.00K 10-Q · filed 2023-05-09 | |
| 2022-12-31 | -$96.00K 10-K · filed 2024-03-28 | -$95.87K 10-K · filed 2023-03-21 |
| 2022-09-30 | -$92.00K 10-Q · filed 2022-11-14 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-21 | |
| 2020-12-31 | $7.13K 10-K · filed 2022-03-16 | |
| 2020-09-30 | $72.00K 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $155.00K 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $249.00K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$10.32K 10-K · filed 2021-03-09 | |
| 2019-03-31 | -$3.00K 10-Q · filed 2019-05-08 | |
| 2018-12-31 | -$10.96K 10-K · filed 2020-03-12 | |
| 2018-09-30 | -$20.00K 10-Q · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |